BioChem - DOS

Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial

International journal of molecular sciences

Calvani, Riccardo; Gervasoni, Jacopo; Picca, Anna; Ciciarello, Francesca; Galluzzo, Vincenzo; Coelho-Jú nior, Hé lio José Di Mario, Clara; Gremese, Elisa; Lomuscio, Sara; Paglionico, Anna Maria; Santucci, Lavinia; Tolusso, Barbara; Urbani, Andrea; Marini, Federico; Marzetti, Emanuele; Landi, Francesco; Tosato, Matteo

<P>Altered <SMALL>L</SMALL>-arginine metabolism has been described in patients with COVID-19 and has been associated with immune and vascular dysfunction. In the present investigation, we determined the serum concentrations of <SMALL>L</SMALL>-arginine, citrulline, ornithine, monomethyl-<SMALL>L</SMALL>-arginine (MMA), and symmetric and asymmetric dimethylarginine (SDMA, ADMA) in adults with long COVID at baseline and after 28-days of <SMALL>L</SMALL>-arginine plus vitamin C or placebo supplementation enrolled in a randomized clinical trial, compared with a group of adults without previous history of SARS-CoV-2-infection. <SMALL>L</SMALL>-arginine-derived markers of nitric oxide (NO) bioavailability (i.e., <SMALL>L</SMALL>-arginine/ADMA, <SMALL>L</SMALL>-arginine/citrulline+ornithine, and <SMALL>L</SMALL>-arginine/ornithine) were also assayed. Partial least squares discriminant analysis (PLS&#x2013;DA) models were built to characterize systemic <SMALL>L</SMALL>-arginine metabolism and assess the effects of the supplementation. PLS&#x2013;DA allowed discrimination of participants with long COVID from healthy controls with 80.2 ± 3.0% accuracy. Lower markers of NO bioavailability were found in participants with long COVID. After 28 days of <SMALL>L</SMALL>-arginine plus vitamin C supplementation, serum <SMALL>L</SMALL>-arginine concentrations and <SMALL>L</SMALL>-arginine/ADMA increased significantly compared with placebo. This supplement may therefore be proposed as a remedy to increase NO bioavailability in people with long COVID. </P>

2023

MDPI

1661-6596

1422-0067

24

6

pp.5078

10.3390/ijms24065078

http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=05787966&target=NART&cn=NART123895353

post-acute COVID-19 syndrome; SARS-CoV-2; ADMA; flow-mediated dilation; nitric oxide; nutraceuticals; oral supplement; persistent symptoms; endothelial dysfunction; metabolomics